Log in

NASDAQ:AGEN - Agenus Stock Price, Forecast & News

$3.83
-0.05 (-1.29 %)
(As of 12/13/2019 07:49 AM ET)
Today's Range
$3.81
Now: $3.83
$3.97
50-Day Range
$2.41
MA: $3.58
$4.41
52-Week Range
$1.95
Now: $3.83
$4.57
Volume543,495 shs
Average Volume1.49 million shs
Market Capitalization$526.09 million
P/E RatioN/A
Dividend YieldN/A
Beta2.06
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AGEN
CUSIP00847G70
Phone781-674-4400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.78 million
Book Value($1.45) per share

Profitability

Net Income$-159,690,000.00
Net Margins-107.15%

Miscellaneous

Employees294
Market Cap$526.09 million
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive AGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.


Agenus (NASDAQ:AGEN) Frequently Asked Questions

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

How were Agenus' earnings last quarter?

Agenus Inc (NASDAQ:AGEN) posted its quarterly earnings data on Monday, November, 4th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.38) by $0.05. The biotechnology company had revenue of $19.94 million for the quarter, compared to the consensus estimate of $15.60 million. View Agenus' Earnings History.

When is Agenus' next earnings date?

Agenus is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Agenus.

What price target have analysts set for AGEN?

1 equities research analysts have issued twelve-month price targets for Agenus' stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Agenus' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 56.7% from the stock's current price. View Analyst Price Targets for Agenus.

What is the consensus analysts' recommendation for Agenus?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agenus.

Has Agenus been receiving favorable news coverage?

News coverage about AGEN stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Agenus earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Agenus.

Who are some of Agenus' key competitors?

What other stocks do shareholders of Agenus own?

Who are Agenus' key executives?

Agenus' management team includes the folowing people:
  • Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 66)
  • Dr. Jennifer Buell, Chief Operating Officer
  • Dr. Alexander R. Duncan, CTO & Head of Research (Age 57)
  • Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 51)
  • Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 53)

Who are Agenus' major shareholders?

Agenus' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (1.75%), Millennium Management LLC (0.55%), Alps Advisors Inc. (0.20%), California Public Employees Retirement System (0.13%), California State Teachers Retirement System (0.12%) and Barclays PLC (0.05%). View Institutional Ownership Trends for Agenus.

Which institutional investors are selling Agenus stock?

AGEN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Barclays PLC, Alberta Investment Management Corp, Metropolitan Life Insurance Co NY and Alps Advisors Inc.. View Insider Buying and Selling for Agenus.

Which institutional investors are buying Agenus stock?

AGEN stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Millennium Management LLC, California Public Employees Retirement System, Commonwealth Equity Services LLC, Virtu Financial LLC and California State Teachers Retirement System. View Insider Buying and Selling for Agenus.

How do I buy shares of Agenus?

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $3.83.

How big of a company is Agenus?

Agenus has a market capitalization of $526.09 million and generates $36.78 million in revenue each year. The biotechnology company earns $-159,690,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Agenus employs 294 workers across the globe.View Additional Information About Agenus.

What is Agenus' official website?

The official website for Agenus is http://agenusbio.com/.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]


MarketBeat Community Rating for Agenus (NASDAQ AGEN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  404 (Vote Outperform)
Underperform Votes:  312 (Vote Underperform)
Total Votes:  716
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel